Study for treatment of gout in older adults with cardiovascular comorbidities

You may qualify to participate if you are: Female, 55 years or older; Male, 50 years or older; have gout and a history of cardiac disease like stroke or heart attack or blood circulation problems.

Study phase (if other): 3b

Additional information:

This is a 9-year study to evaluate the safety of Febuxostat and Allopurinol. Study-related medical care and services are provided at no cost to study participants.

Primary disease category: Arthritis

Secondary disease categories: Heart/Cardiovascular, Arthritis

Sponsor: Takeda Development Center Americas, Inc.

Protocol number: TMX-67_301

Projected enrollment dates: January 2014 to February 2017

Official study title: A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities